

TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
3829.02-1

Application Of: WILLIAM J. WECHTER

Serial No. 10/734,687	Filing Date DECEMBER 11, 2003	Examiner N/A	Group Art Unit N/A
--------------------------	----------------------------------	-----------------	-----------------------

Title: METHODS FOR SCREENING COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE

TO THE COMMISSIONER FOR PATENTS:

Transmitted herewith is:

1. TRANSMITTAL LETTER;
2. TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT;
3. PTO FORM 1449;
4. COPIES OF REFERENCES A-U); AND
5. POSTCARD.

in the above identified application.

No additional fee is required.

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 16-1331 as described below.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

Hana Verry
Signature

Dated: MARCH 15, 2004

HANA VERNY (REG. NO. 30,518)
PETERS, VERNY, JONES & SCHMITT, L.L.P.
425 SHERMAN AVENUE, SUITE 230
PALO ALTO, CA 94306
TEL: (650)324-1677
FAX: (650)324-1678

I certify that this document and fee is being deposited on MARCH 15, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Melinda Tompkins
Signature of Person Mailing Correspondence

MELINDA TOMPKINS


Typed or Printed Name of Person Mailing Correspondence

cc:

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
3829.02-1

In Re Application Of: **WECHTER**



Serial No.
10/734,687

Filing Date
DECEMBER 11, 2003

Examiner
N/A

Group Art Unit
N/A

Title: **METHODS FOR SCREENING COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE**

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);


OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(e))

Docket No.
3829.02-1

In Re Application: WECHTER



Serial No.
10/734,687

Filing Date
DECEMBER 11, 2003

Examiner
N/A

Group Art Unit
N/A

METHODS FOR SCREENING COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 16-1331 as described below.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:


(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on MARCH 15, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Signature of Person Mailing Correspondence

MELINDA TOMPKINS

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.



Signature

HANA VERNY (REG. NO. 30,518)

PETERS, VERNY, JONES & SCHMITT, L.L.P.

425 SHERMAN AVENUE, SUITE 230

PALO ALTO, CA 94306

TEL: (650)324-1677

FAX: (650)324-1678

CC:

Dated: MARCH 15, 2004

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANTS INFORMATION DISCLOSURE
STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.

3829.02-1

SERIAL NO.

10/734,687

APPLICANT : WECHTER

FILING DATE : DECEMBER 11, 2003

GROUP N/A

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
						TRANSLATION	YES
			US				

OTHER

ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	A	Romualda D. Knihinicki, et al., Chiral Inversion of 2-Arylpropionic Acid Non-Steroidal Anti-Inflammatory Drugs - II, <u>Biochemical Pharmacology</u> , 42/10: 1905-1911 (1991).
	B	S. Ferdinandusse, et al., Stereochemistry of the Peroxisomal Branched-Chain Fatty Acid Alpha- and Beta-Oxidation Systems in Patients Suffering From Different Peroxisomal Disorders, <u>Journal of Lipid Research</u> , 43:438-444 (2002).
	C	Christine Reichel, et al., 2-Arylpropionyl-CoA Epimerase: Partial Peptide Sequences and Tissue Localization, <u>Biochemical Pharmacology</u> , 50/11:1803-1806 (1995).
	D	Timothy S. Tracy, et al., Metabolic Inversion of (R)-Ibuprofen, Formation of Ibuprofenyl-Coenzyme A, <u>Drug Metabolism and Disposition</u> , 21/1: 114-120 (1993).
	E	Christine Reichel, et al., Molecular Cloning and Expression of a 2-Arylpropionyl-Coenzyme A Epimerase: A Key Enzyme in the Inversion Metabolism of Ibuprofen, <u>Molecular Pharmacology</u> , 51:576-582 (1997).
	F	Ching-Shih Chen, et al., Metabolic Stereoisomeric Inversion of Ibuprofen in Mammals, <u>Biochimica et Biophysica Acta</u> 1078:411-417 (1991).
	G	Tiina J. Kotti, et al., In Mouse Alpha-Methylacyl-CoA Racemase, the Same Gene Product is Simultaneously Located in Mitochondria and Peroxisomes, <u>The Journal of Biochemical Chemistry</u> , 275/27:20887-20895 (2000).
	H	Woan-Ru Shieh, et al., Purification and Characterization of Novel "2-Arylpropionyl-CoA Epimerases" From Rat Liver Cytosol and Mitochondria, <u>The Journal of Biological Chemistry</u> , 268/5:3487-3493 (1993).
	I	Leen Amery, et al., Mitochondrial and Peroxisomal Targeting of 2-Methylacyl-CoA Racemase in Humans, <u>Journal of Lipid Research</u> , 41:1752-1759 (2000).
	J	Jun Luo, et al., Alpha-Methylacyl-CoA Racemase: A New Molecular Marker for Prostate Cancer, <u>Cancer Research</u> , 62:2220-2226 (April 15, 2002).
	K	Rainer Kuefer, et al., Alpha-Methylacyl-CoA Racemase: Expression Levels of This Novel Cancer Biomarker Depend on Tumor Differentiation, <u>American Journal of Pathology</u> , 161/3:841-848 (September 2002).
	L	Mark A. Rubin, et al., Alpha-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer, <u>JAMA</u> , 287/13:1662-1670 (April 3, 2002).
	M	Zhong Jiang, et al., P504S/Alpha-Methylacyl-CoA Racemase, A Useful Marker for Diagnosis of Small Foci of Prostatic Carcinoma on Needle Biopsy, <u>The American Journal of Surgical Pathology</u> , 26/9:1169-1174 (2002).
	N	Jiangchun Xu, et al., Identification of Differentially Expressed Genes in Human Prostate Cancer Using Subtraction and Microarray, <u>Cancer Research</u> , 60:1677-1682 (March 15, 2000).
	O	Zhong Jiang, et al., P504S, A New Molecular Marker for the Detection of Prostate Carcinoma, <u>The American Journal of Surgical Pathology</u> , 25/11:1397-1404 (2001).
	P	Ximing J. Yang, et al., Expression of Alpha-Methylacyl-CoA Racemase (P504S) in Atypical Adenomatous Hyperplasia of the Prostate, <u>The American Journal of Surgical Pathology</u> , 26/7:921-925 (2002).
	Q	Diqun L. Zheng, et al., Sequence Variants of Alpha-Methylacyl-CoA Racemase Are Associated with Prostate Cancer Risk, <u>Cancer Research</u> , 62:6485-6488 (November 15, 2002).
	R	Sacha Ferdinandusse, et al., Subcellular Localization and Physiological Role of Alpha-Methylacyl-CoA Racemase, <u>Journal of Lipid Research</u> , 41:1890-1896 (2000).
	S	Werner Schimitz, et al., Molecular Cloning of cDNA Species for Rat and Mouse Liver Alpha-Methylacyl-CoA Racemases, <u>Biochem J.</u> , 326:883-889 (1997).

	T	Ming Zhou, et al., Alpha-Methylacyl-CoA·Racemase, A Novel Tumor Marker Over-Expressed in Several Human Cancers and Their Precursor Lesions, <u>The American Journal of Surgical Pathology, 26/7:926-931 (2002)</u> .
	U	Sacha Ferdinandusse, et al., Plasma Analysis of Di- and Trihydroxycholestanic Acid Diastereoisomers in Peroxisomal Alpha-Methylacyl-CoA Racemase Deficiency, <u>Journal of Lipid Research, 42:137-141 (2001)</u> .

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.